Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
MindWalk Holdings (NASDAQ: HYFT) reported that over 20 drug candidates in partner pipelines originated from its antibody discovery work, with 10 programs now in active Phase 1–3 clinical trials across oncology, immunology, neurology, and infectious disease.
The company highlighted its HYFT® and LensAI™ biological intelligence infrastructure, built on a Knowledge Graph indexing 660 million biological patterns and 25 billion relationships, and a record of 400+ peer-reviewed publications and patents supporting collaborations with firms such as Annexon, argenx, Xencor, Cullinan Oncology, and others.
Xencor (NASDAQ:XNCR) reported Q1 2026 results and pipeline progress on May 6, 2026. Cash, cash equivalents and marketable securities were $541.8M at March 31, 2026; company expects $380M–$400M year-end 2026 and funding into mid‑2028. Q1 revenue was $4.5M (includes a $6.6M one‑time royalty reduction); Q1 net loss was $128.9M or $(1.71) per share. Key clinical milestones: XmAb819 expansion cohort data due 2H26; XmAb412 first‑in‑human planned 3Q26; XENITH‑UC blinded interim analysis expected around year‑end 2026.
Xencor (NASDAQ:XNCR) presented Phase 1 final results for XmAb942 and preclinical data for XmAb412 at DDW and will host a webcast on May 5 at 8:00 a.m. EDT. XmAb942 showed a 74.1-day terminal half-life, supports a single subcutaneous 12-week maintenance dose, and informs a ~220-patient Phase 2b XENITH-UC study with a blinded interim around year-end 2026 and primary endpoint readout in H2 2027. XmAb412 (TL1A x IL23p19) is planned to enter first-in-human healthy-participant dosing in 3Q26; predicted human half-life 60–70 days and single-/sub-picomolar affinities were reported.
Xencor (NASDAQ:XNCR) announced that its licensee for Ultomiris informed Xencor it believes no additional U.S. royalties are owed and does not intend future U.S. payments, while continuing ex-U.S. payments. Xencor said it will seek resolution and conservatively updated cash runway to mid-2028.
The company reiterated issuance of U.S. Patent 12,492,253 and had previously expected an estimated $100–$120 million aggregate in low single-digit royalties from Ultomiris U.S. sales through 2028. Xencor expects $380–$400 million in cash and equivalents at year-end 2026.
Xencor (NASDAQ:XNCR) reported Q4 2025 and full-year results, highlighted by $610.8M in cash at year-end, Q4 revenue $28.2M and full-year revenue $125.6M. The company advanced multiple clinical programs including XmAb819 dose-expansion, XmAb942 Phase 2b enrollment, and plans for XmAb412 first-in-human in 2H26.
Guidance: Xencor expects year-end 2026 cash of $400–$430M and sufficient resources to fund operations through 2028. The company also estimates potential Xtend royalty revenue of $100–$120M through 2028.
Xencor (NASDAQ:XNCR) management will present at three investor conferences in early March 2026: TD Cowen on March 2, Leerink Partners on March 10, and Barclays on March 11.
Presentation times are listed in ET and PT. Live webcasts will be available under Events & Presentations on the company website, with replays accessible for at least 30 days.
Xencor (NASDAQ:XNCR) outlined 2026 corporate priorities and clinical milestones across five wholly owned XmAb® clinical-stage candidates. Key clinical readouts planned in 2026 include new data to support recommended Phase 3 doses for XmAb819 and XmAb541 in 2H26, Phase 1 updates for plamotamab and XmAb657 in 2H26, final Phase 1 healthy-volunteer results for XmAb942 in 1H26, and a first-in-human study start for XmAb412 in 2H26. Prior clinical results cited: XmAb819 showed a 25% partial response rate (20 evaluable patients) and a 70% disease control rate. Xencor ended Q4 2025 with approximately $611 million in unaudited cash, cash equivalents and marketable debt securities, which the company expects will fund operations through 2028.
Xencor (NASDAQ:XNCR) announced issuance of U.S. Patent 12,492,253 covering its Xtend™ Fc domain for C5-targeting antibodies, extending the U.S. patent term into December 2028—about three years longer than the prior latest-to-expire U.S. Xtend patent. Xencor expects to receive low-single-digit royalties on U.S. sales of Ultomiris (ravulizumab-cwvz) through December 2028.
The company estimates an additional $100–$120 million of potential royalty revenue for the extended term based on consensus Ultomiris sales forecasts. OMERS acquired royalties with annual caps up to $35 million for 2026–2028. Xencor recognized $51.0 million of non-cash royalty revenue for the nine months ended September 30, 2025.
Xencor (NASDAQ:XNCR) announced management will participate in two investor conferences in late 2025: the TD Cowen Immunology and Inflammation Virtual Summit on Wednesday, November 12, 2025 at 3:00 p.m. ET / 12:00 p.m. PT, and the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 2:00 p.m. ET / 11:00 a.m. PT.
Both presentations will be available via live webcast under the company’s Investors & Events section at www.xencor.com. Replays will be posted on the Xencor website for at least 30 days after the events.
Xencor (NASDAQ:XNCR) reported third quarter 2025 results and clinical updates on November 5, 2025. Q3 revenue was $21.0M vs $17.8M year-ago. Cash, cash equivalents and marketable debt securities were $633.9M at September 30, 2025 and the company expects to end 2025 with $570M–$590M, providing runway into 2028. Net loss was $6.0M, or $(0.08) per share, versus $(0.72) in Q3 2024. Other income increased to $41.5M driven by unrealized gains.
Clinical: XmAb819 and XmAb541 showed early anti-tumor activity with planned recommended Phase 3 dose selection in 2026 and pivotal study starts in 2027; XmAb942 and plamotamab advanced into Phase 2b and Phase 1b studies, respectively.